Cytosystems
Aberdeen, Aberdeen City, United Kingdom
About Cytosystems
Cytosystems is a pathology company that develops non-invasive cancer diagnostic and stratification technologies for initially for the management of bladder cancer. The company’s first product, BladderLight™, is an integrated and automated digital pathology solution using a big data systems approach for the diagnosis and monitoring of bladder cancer. Cytosystems has developed two patent-pending technologies: a point of care cell collection device which optimizes analyte quality at point of patient care and the use of artificial intelligence pattern recognition software to interrogate and objectively classify individual urothelial cells as cancer positive or negative. This whole-cell approach can help with clinical decision making and provides a highly sensitive and specific test which achieves the challenging performance levels demanded of a non-invasive test by patients and clinicians.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $3.7M
- Funding stage: Seed
- Last round: Grant (Jan 2015)
- Website: cytosystems.com
- Phone: +44 (0)1224 711375
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Hospital, Medical
Social Profiles
Canonical: https://fsome.com/organization/cytosystems-2482793 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.